Study on the Loading and Releasing Behavior of EpirubicinHydrochloride from Mesoporous Bioactive Glasses (MBGs)

doi:10.3724/SP.J.1077.2011.00068

Abstract

Abstract: Mesoporousbioactive glasses m58S were loaded with an anticancer drug-Epirubicin hydrochloride(EPI) and the release of the drug from the glasses was evaluated. The drugloading capacity of m58S for EPI was 40%, which was three times higher thanthat of conventional Sol-Gel bioactive glasses 58S. In phosphate buffered saline (PBS), the m58S-EPI system showed asustained release behavior. Furthermore, the release rates from the EPI-m58Ssystem increased with the decrease of pH values of the release medium. Theresults suggest that m58S is an effective anticancer drug carrier and itspH-related release behavior suggests that it has potential for design ofcontrolled drug delivery bone grafting materials.

Key words: bioactive glasses, mesoporous materials, drug delivery system

CLC Number:

R318

ZHOU Yan-Ling, FENG Xin-Xing, ZHAI Wan-Yin, CHANG Jiang. Study on the Loading and Releasing Behavior of EpirubicinHydrochloride from Mesoporous Bioactive Glasses (MBGs)[J]. Journal of Inorganic Materials, 2011, 26(1): 68-72.

References

[1] Wang T W, Wu H C, Wang WR, et al. The development of magneticdegradable DP-bioglass for hyperthermia cancer therapy. J. Biomed. Mater. Res. B, 2007, 83A: 828-837.
[2] Geraci M, Birch J M,Alston R D, et al. Cancer mortalityin 13 to 29-year-olds in England and Wales, 1981-2005. Br. J. Cancer, 2007, 97: 1588-1594.
[3] Schulman K L, Kohles J.Economic burden of metastatic bone disease in the US. Cancer, 2007, 109(11): 2334-2342.
[4] Anderson P,Salazar-Abshire M. Improving outcomes in difficult bone cancers usingmultimodality therapy, including radiation: physician and nursing perspectives.Curr. Oncol. Rep., 2006, 8(6): 415-422.
[5] Arndt C A S, Crist W M.Medical progress-common musculoskeletal tumors of childhood and adolescence. New. Eng. J. Med., 1999, 341(5): 342-352.
[6] MarinaN, Gebhardt M, Teot L, et al. Biologyand therapeutic advances for pediatric osteosarcoma. Oncologist, 2004, 9(4):422-441.
[7] Sandberg A A, Bridge J A.Updates on the cytogenetics and molecular genetics of bone and soft tissuetumors: osteosarcoma and related tumors. CancerGenet. Cytogen., 2003, 145(1): 1-30.
[8] BagiC M. Targeting oftherapeutic agents to bone to treat metastatic cancer. Adv. Drug Delivery Rev., 2005, 57(7):995-1010.
[9] Guise T A, Mundy G R. Cancerand bone. Endocr. Rev., 1998, 19(1): 18-54.
[10]Nagarajan R, Clohisy D R, Neglia J P, et al. Function and quality-of-life of survivors of pelvic andlower extremity osteosarcoma and Ewing's sarcoma: the childhood cancer survivorstudy. Br. J. Cancer, 2004, 91(11): 1858-1865.
[11]Meyer J S, Mackenzie W. Malignant bone tumors andlimb-salvage surgery in children. Pediatr.Radiol., 2004, 34(8): 606-613.
[12]Felder-Puig R, Formann A K, Mildner A, et al. Quality of life and psychosocial adjustment of youngpatients after treatment of bone cancer. Cancer,1998, 83(1): 69-75.
[13]Serrano M C, Portoles M T, Pagani R, et al. <>In vitro positive biocompatibility evaluation ofglass-glass ceramic thermoseeds for hyperthermic treatment of bone tumors. Tissue Eng. A, 2008, 14(5): 617-627.
[14]Lindfors N C, Heikkila J T, Aho A J. Long-term evaluation ofblood silicon and ostecalcin in operatively treated patients with benign bonetumors using bioactive glass and autogenous bone. J. Biomed. Mater. Res. B, 2008, 87B(1): 73-76.
[15]Takegami K, Sano T, Wakabayashi H, et al. New ferromagnetic bone cement for local hyperthermia. J. Biomed. Mater. Res., 1998, 43(2): 210-214.
[16]Hench L L. Bioceramics. J. Am. Ceram. Soc., 1998, 81(7):1705-1728.
[17]Hench L L. Bioceramics-from concept to clinic. J. Am. Ceram. Soc., 1991, 74(7): 1487-1510.
[18]Yan X X, Yu C Z, Zhou X F,et al. Highly ordered mesoporous bioactive glasses with superior in vitrobone-forming bioactivities. Angew. Chem. Int.Ed, 2004, 43(44): 5980-5984.
[19]Xia W, Chang J. Well-ordered mesoporous bioactiveglasses (MBG): A promising bioactive drug delivery system. J. Controlled Release, 2006, 110(3):522-530.
[20]Xia W, Chang J, Lin J P, etal. The pH-controlled dual-drug release from mesoporous bioactiveglass/polypeptide graft copolymer nanomicelle composites. Eur. J. Pharm. Biopharm, 2008, 69(2): 546-552.
[21]Xia W, Chang J. Preparation, <>in vitrobioactivity and drug release property of well-ordered mesoporous 58S bioactiveglass. J. Non-Cryst. Solids, 2008, 354(12/13): 1338-1341.
[22]Kumar D, Tomar R S, Deolia S K, et al. Isolation and characterization of degradation impurities inepirubicin hydrochloride injection. J. Chromatogr.B, 2008, 869(1/2): 45-53.
[23]Ozdemir F A, Anilanmert B, Pekin M. Spectrophotometricinvestigation of the chemical compatibility of the anticancer drugsirinotecan-HCI and epirubicin-HCI in the same infusion solution. Cancer Chemoth. Pharm, 2005, 56(5): 529-534.
[24]Kelso E J, Geraghty R F, McDermott B J, et al. Characterisation of a cellular model of cardiomyopathy, inthe rabbit, produced by chronic administration of the anthracycline,epirubicin. J. Mol. Cell Cardiol.,1997, 29(12): 3385-3397.
[25]Masuda N, Amani S, Nishikata M, et al. Appropriate solution selection at the administeringepirubicin hydrochloride to the breast cancer patients. <>European Journal ofCancer Supplements, 2004, 2(3):145.
[26]Nielsen O S, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not analternative to standard-dose doxorubicin in the treatment of advanced softtissue sarcomas. a study of the EORTC soft tissue and bone sarcoma group. Br. J. Cancer, 1998, 78(12): 1634-1639.
[27]刘勤江, 田尤新, 肖忆南. 阿霉素在肿瘤局部化疗中的应用研究.肿瘤学杂志, 2004, 10(1): 45-47.
[28]Oonishi H, Kushitani S, Yasukawa E, et al. Particulate bioglass compared with hydroxyapatite as a bonegraft substitute. Clin. Orthop. Relat.Res., 1997, 334: 316-325.
[29]Oonishi H, Hench L L, Wilson J, et al. Comparative bone growth behavior in granules of bioceramicmaterials of various sizes. J. Biomed.Mater. Res., 1999, 44(1): 31-43.
[30]Zhong J P, Greenspan D C. Processing and propertiesof Sol-Gel bioactive glasses. J. Biomed.Mater. Res., 2000, 53(6): 694-701.
[31]Chen Q Z, Ahmed I, Knowles J C, et al. Collagen release kinetics of surface functionalized 4555Bioglass^®-based porous scaffolds. J. Biomed. Mater. Res. A, 2008, 86A(4): 987-995.
[32]Erdinc N, Gokturk S, Tuncay W. Interaction of epirubicinHCl with surfactants: effect of NaCl and glucose. J. Pharm. Sci., 2004, 93(6):1566-1576.
[33]Li X, Zhang L X, Dong X P, <>et al. Preparation of mesoporous calcium doped silica spheres withnarrow size dispersion and their drug loading and degradation behavior. Microporous. Mesoporous. Mater., 2007, 102(1/2/3): 151-158.
[34]Zhao D Y, Feng J L, Huo Q S, et al. Triblock copolymer syntheses of mesoporous silica withperiodic 50 to 300 angstrom pores.Science, 1998, 279(5350): 548-552.
[35]Guo M, Yan Y, Zhang H K,et al. Magnetic and pH-responsive nanocarriers with multilayer core-shellarchitecture of anticancer drug delivery. J.Mater. Chem., 2008, 18(42): 5104-5112.
[36]Pal R, Kundu D. Sol-Gel synthesis of porous anddense silica microspheres. J. Non-Cryst.Solids, 2009, 355(1): 76-78.